请选择 进入手机版 | 继续访问电脑版
楼主: william9225
2079 6

[其他] 【商业故事】Samsung Makes Play for Drug Market With Cheaper Blockbuster Humira [推广有奖]

版主

巨擘

0%

还不是VIP/贵宾

-

TA的文库  其他...

文库之星

【William新闻精选】

2019经济报刊周刊精选

威望
15
论坛币
1437679 个
通用积分
153.2405
学术水平
3616 点
热心指数
3969 点
信用等级
3571 点
经验
676818 点
帖子
18353
精华
60
在线时间
4871 小时
注册时间
2015-2-12
最后登录
2024-2-21

william9225 学生认证  发表于 2017-6-23 20:49:57 |显示全部楼层 |坛友微信交流群
相似文件 换一批

+2 论坛币
k人 参与回答

经管之家送您一份

应届毕业生专属福利!

求职就业群
赵安豆老师微信:zhaoandou666

经管之家联合CDA

送您一个全额奖学金名额~ !

感谢您参与论坛问题回答

经管之家送您两个论坛币!

+2 论坛币
source from:wsj
BUSINESS
Samsung Makes Play for Drug Market With Cheaper Version of Blockbuster Humira
South Korean conglomerate’s arm Samsung Bioepis set for European approval of its biosimilar version of the rheumatoid-arthritis treatment
屏幕快照 2017-06-23 20.00.38.png

By Timothy W. Martin in Seoul and Jonathan D. Rockoff in New York
June 23, 2017 7:33 a.m. ET
0 COMMENTS
A Samsung group arm is on track to win European regulatory approval for a near-replica version of the world’s top-selling drug, AbbVie Inc.’s rheumatoid-arthritis treatment Humira, the latest achievement by the deep-pocketed South Korean conglomerate attempting to shake up the pharmaceutical market.

Samsung Bioepis Co., the group’s new biotechnology company, said in a statement Friday that it had received a positive opinion from the European Medicines Agency for its treatment, known as Imraldi. That decision clears the way for approval from the European Commission, whose judgment typically mirrors that of the EMA.

If it gets the green light, Imraldi would represent the third Samsung-developed medication to win government approval in Europe and the U.S--an unusually fast start for a five-year-old company, industry analysts say. All three Samsung treatments are close imitations of rheumatoid-arthritis drugs that rank among the world’s biggest sellers.

In April, Samsung’s version of Johnson & Johnson ’s Remicade won U.S. Food and Drug Administration approval to begin sales later this year. In Europe, Samsung has sold the Remicade near-replica and its version of Pfizer Inc.’s Enbrel since last year.

Biologic drugs, such as Humira or Remicade, are made out of living cells and treat complex diseases including cancer or arthritis. Annual treatments can total tens of thousands of dollars a year—if not more, making them one of the most lucrative segments of the drug industry.

However, with patent protections expiring, Samsung and other new players have been working to produce lower-priced near-replicas of biologic drugs, akin to the generic versions of chemically synthesized drugs like aspirin. Efforts to sell--or block--these biosimilar treatments have led to a flood of lawsuits in the U.S. and Europe.

In this world, Samsung, an empire accounting for nearly one-third of South Korea’s stock-market value, ranks as an unusual player: a well-resourced competitor whose fortunes aren’t solely tethered to global health spending but spread across other industries from consumer electronics to construction.

Samsung’s Imraldi treatment, if approved by the European Commission, would be the second near-replica of Humira to receive regulatory backing, after Amgen Inc.’s version was approved in the U.S. and Europe in September 2016 and March 2017, respectively.

Humira, which is also used to treat other autoimmune diseases and is administered through injections, racked up more than $16 billion in global sales last year. A year’s supply of Humira has a retail price of more than $50,000 in the U.S., with the costs varying by country in Europe.

Christopher Ko, Samsung Bioepis’s chief executive, said in a statement that the EMA’s decision “brings us a step closer to delivering a lower-cost, high-quality autoimmune treatment option to patients.”

Industry analysts expect Samsung, Amgen and other drugmakers will be able to roll out Humira biosimilars in Europe after AbbVie’s main patent on the drug there expires in October 2018.

Samsung, Amgen and other drugmakers will be able to roll out Humira biosimilars in Europe after AbbVie’s main patent on the drug there expires in October 2018.

In an echo of Samsung’s earlier shift to focus on semiconductors and smartphones, the conglomerate has recently begun to embrace complex medicines as a potential source of growth.

In addition to Samsung Bioepis’s development of biosimilars of drugs whose patents are set to soon expire, another new Samsung affiliate, Samsung BioLogics Co. , is investing heavily to become the world’s largest contract manufacturer of biologic drugs.

二维码

扫码加我 拉你入群

请注明:姓名-公司-职位

以便审核进群资格,未注明则拒绝

关键词:Samsung market block makes marke

本帖被以下文库推荐

hjtoh 发表于 2017-6-23 21:28:26 来自手机 |显示全部楼层 |坛友微信交流群
william9225 发表于 2017-6-23 20:49
source from:wsj
BUSINESS
Samsung Makes Play for Drug Market With Cheaper Version of Blockbuster H ...
三星还是走在前面的,我们不能只是跟风

使用道具

h2h2 发表于 2017-6-24 04:41:15 |显示全部楼层 |坛友微信交流群
谢谢分享

使用道具

MouJack007 发表于 2017-6-24 05:22:53 |显示全部楼层 |坛友微信交流群
谢谢楼主分享!

使用道具

MouJack007 发表于 2017-6-24 05:23:10 |显示全部楼层 |坛友微信交流群

使用道具

啸傲江弧 发表于 2017-6-24 05:55:04 |显示全部楼层 |坛友微信交流群
Thanks for sharing!

使用道具

啸傲江弧 发表于 2017-6-24 05:55:49 |显示全部楼层 |坛友微信交流群

使用道具

您需要登录后才可以回帖 登录 | 我要注册

本版微信群
加JingGuanBbs
拉您进交流群

京ICP备16021002-2号 京B2-20170662号 京公网安备 11010802022788号 论坛法律顾问:王进律师 知识产权保护声明   免责及隐私声明

GMT+8, 2024-3-29 06:35